
Dr. Lal Pathlabs (LALPATHLAB) Share Price Fall Streak Extends to Second Straight Session Decline
Updated: 1 Oct 2026 • 9:54 am
Posted by:

Dr. Lal Pathlabs Share Price Fall Streak now covers the second straight session, with the stock trading at Rs 1,947.15 after a cumulative 0.46% decline across the run. According to Univest data, the price pattern is confirmed, but no company-specific catalyst is established. The move keeps Dr. Lal Pathlabs Share Price Fall Streak in focus because consecutive lower closes matter more than a single-day move: they show that the decline has persisted across sessions rather than appearing as an isolated swing.
Dr. Lal Pathlabs carries a market capitalisation of Rs 32,833.75 Cr, so the streak is meaningful for a large listed healthcare business rather than a smaller counter. For a reader tracking Dr. Lal Pathlabs Share Price Fall Streak, the key point is that the latest move sits within a broader run of lower closes and not a one-off intraday dip. That makes the current Dr. Lal Pathlabs Share Price Fall Streak worth reading alongside valuation, sector comparison and peer positioning.
Dr. Lal Pathlabs (LALPATHLAB) Share Price Fall Streak: Consecutive Decline Analysis
| Metric | Value |
|---|---|
| Current Price | Rs 1,947.15 |
| Previous Close | Rs 1,987.6 |
| Today's Move | -Rs 40.45 (-2.04%) |
| Open | Rs 1,973.7 |
| High | Rs 1,973.7 |
| Low | Rs 1,937.1 |
| Market Capitalisation | Rs 32,833.75 crore |
Dr. Lal Pathlabs Share Price Fall Streak continued as the stock traded at Rs 1,947.15, down Rs 40.45 or 2.04% from the previous close of Rs 1,987.60. The session opened at Rs 1,973.70, touched a high of Rs 1,973.70 and a low of Rs 1,937.10, with the last trade sitting much closer to the lower end of that range. The market capitalisation stood at Rs 32,833.75 Cr, which places the company in the Large Cap category and gives the move a visible impact on headline valuation. For Dr. Lal Pathlabs Share Price Fall Streak, the key takeaway is that the stock did not recover back toward the opening level during the session. Dr. Lal Pathlabs Share Price Fall Streak also matters because the latest trade extends the second straight session of lower closes, so the move should be read as a short run of weakness rather than a single isolated slide. The price action now leads naturally into the valuation discussion that follows.
What the Consecutive Declines Show
Dr. Lal Pathlabs Share Price Fall Streak is the main lens for this update because the stock has now closed lower for the second straight session, with a cumulative change of -0.46% from the streak start base price of Rs 1,956.15. That cumulative figure is much smaller than the latest daily decline, which tells readers that the two sessions have not moved in the same magnitude. Instead, the pattern shows a continued drift lower across sessions. Univest figures confirm the price action, but they do not point to a specific company trigger. For Dr. Lal Pathlabs Share Price Fall Streak, that distinction matters: the streak is about persistence, not just the size of one trading day. The business is still the same company with the same earnings base and book value base, but the market price has moved lower, which is what changes the share-price lens.
Dr. Lal Pathlabs (LALPATHLAB) Fundamental Analysis
| Metric | Value |
|---|---|
| Market Capitalisation | Rs 32,833.75 crore |
| P/E Ratio | 61.56x |
| P/B Ratio | 12.77x |
| ROE | 22.37% |
| ROCE | 29.56% |
| EPS | Rs 32.29 |
| Book Value Per Share | Rs 155.67 |
| Dividend Yield | 1.03% |
Dr. Lal Pathlabs (LALPATHLAB) fundamental metrics show P/E 61.56x, P/B 12.77x, ROE 22.37%, ROCE 29.56%. Taken on their own, these numbers offer context rather than a trading signal.
Dr. Lal Pathlabs has a market capitalisation of Rs 32,833.75 crore and falls in the Large Cap category, which gives readers a sense of company size before judging valuation. On valuation, P/E at 61.56x, P/B at 12.77x should be read against the sector and peer benchmarks rather than as a standalone signal. Profitability is represented by ROE of 22.37% and ROCE of 29.56%, helping investors compare shareholder returns and capital efficiency. According to latest Univest data, additional metrics include EPS of Rs 32.29, book value per share of Rs 155.67, dividend yield of 1.03%, adding context to earnings, balance-sheet value and historical payout. Against the latest Univest same industry benchmark, these figures can be compared with benchmark median P/E of 45.98x, median ROE of 13.01%, median ROCE of 15.84%. They set out the fundamental picture and are not a rating on the stock.
Sector and Industry Context
| Metric | Value |
|---|---|
| Sector | Healthcare |
| Industry | Hospital & Healthcare Services |
| Benchmark Scope | same industry |
| Company P/E Ratio | 61.56x |
| Benchmark Median P/E | 45.98x |
| Benchmark Average P/E | 99.66x |
| Benchmark P/E Range | 6.96x to 1,608.25x |
| Company P/B Ratio | 12.77x |
| Benchmark Median P/B | 3.97x |
| Benchmark Average P/B | 4.61x |
| Company ROE | 22.37% |
| Benchmark Median ROE | 13.01% |
| Benchmark Average ROE | 12.87% |
| Company ROCE | 29.56% |
| Benchmark Median ROCE | 15.84% |
| Benchmark Average ROCE | 2.83% |
| Company Market Capitalisation | Rs 32,833.75 crore |
| Benchmark Median Market Cap | Rs 581.1 crore |
| Benchmark Average Market Cap | Rs 11,299.25 crore |
Dr. Lal Pathlabs (LALPATHLAB) operates in the Healthcare sector, within the Hospital & Healthcare Services industry.
Dr. Lal Pathlabs (LALPATHLAB) has a P/E ratio of 61.56x, which is above the benchmark median of 45.98x, a difference of +33.88%. P/E is a valuation multiple and is not, by itself, a buy or sell signal.
Dr. Lal Pathlabs (LALPATHLAB) has a ROE of 22.37%, which is above the benchmark median of 13.01%, a difference of +71.94%. Dr. Lal Pathlabs (LALPATHLAB) has a ROCE of 29.56%, which is above the benchmark median of 15.84%, a difference of +86.62%.
Track stocks among today's decliners through the Univest top decliners screener. The peer table below provides the company-level comparison.
Peer Comparison
| Company | Symbol | Market Cap (Cr) | P/E | P/B | ROE (%) | ROCE (%) |
|---|---|---|---|---|---|---|
| Apollo Hospitals Enterprise | APOLLOHOSP | 1,25,119.97 | 56 | 12.08 | 23.54 | 21.73 |
| MANIPAL HEALTH ENTERPRI L | MANIPALHOS | 98,508.6 | 104.47 | 5.11 | 12.95 | 13.93 |
| Max Healthcare Institute | MAXHEALTH | 95,768.86 | 62.11 | 8.28 | 14.53 | 14.97 |
| Aster DM Healthcare | ASTERDM | 64,094.07 | 190.26 | 14.33 | 13.07 | 16.22 |
| Fortis Healthcare | FORTIS | 61,831.07 | 55.35 | 5.71 | 11.32 | 14.07 |
Dr. Lal Pathlabs (LALPATHLAB) has a P/E ratio of 61.56x compared with the displayed peer median of 62.11x. The comparison is relative and should not be read as a recommendation. Its ROE of 22.37% compares with a peer median of 13.07% across the companies shown in the table. ROCE stood at 29.56% versus the displayed peer median of 14.97%, providing a capital-efficiency comparison. Dr. Lal Pathlabs (LALPATHLAB) has a market capitalisation of Rs 32,833.75 crore. All 5 peers shown have a larger market capitalisation.
Why Investors Are Watching Dr. Lal Pathlabs
- Dr. Lal Pathlabs Share Price Fall Streak shows a second straight session of lower closes, which keeps the stock in focus for traders tracking price action.
- The current trade at Rs 1,947.15 sits below the previous close, making the move relevant for anyone watching Dr. Lal Pathlabs Share Price Today.
- The company’s P/E of 61.56 and P/B of 12.77 remain well above the sector median, so valuation remains central to Dr. Lal Pathlabs Fundamental Analysis.
- ROE of 22.37% and ROCE of 29.56% still compare favourably with the same-industry benchmark, which keeps the stock interesting for stock analysis.
- The healthcare peer set shows mixed valuation profiles, so Dr. Lal Pathlabs Share Price Fall Streak can be read alongside peer comparison rather than in isolation.
About Dr. Lal Pathlabs
Dr. Lal Pathlabs operates in Healthcare within the Hospital & Healthcare Services industry. The business is known for diagnostic and pathology services, which makes its earnings profile different from a hospital operator even though it sits in the same broad sector benchmark. For Dr. Lal Pathlabs Share Price Fall Streak, that distinction matters because investors are not just looking at one-day price movement; they are also weighing the company’s premium valuation, profitability ratios and large-cap position. The latest share-price move does not change what the company does, but it does change how the market reads the stock against its sector peers.
Track Dr. Lal Pathlabs Share Price on Univest
Use Dr. Lal Pathlabs (LALPATHLAB) live share-price page, Univest top decliners screener, Univest market blogs to review live stock data, top decliners and related market analysis.
Track Dr. Lal Pathlabs Share Price on Univest to follow the latest share price, market capitalisation, valuation ratios and 52-week levels in one place. Dr. Lal Pathlabs Share Price Fall Streak can be monitored alongside fundamental analysis, peer comparison and sector context, all with a clean stock overview for faster reading.
Disclaimer: Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Uniresearch Global Pvt. Ltd. (Research Analyst, SEBI Reg. No. INH000013776, a subsidiary of Univest Communication Technologies Private Limited).
Frequently Asked Questions
Why is Dr. Lal Pathlabs Share Price Fall Streak in focus today?
Ans. Dr. Lal Pathlabs Share Price Fall Streak is in focus because the stock has closed lower for the second straight session. The latest trade was Rs 1,947.15, down 2.04% from the previous close.
What is the current Dr. Lal Pathlabs Share Price?
Ans. The current Dr. Lal Pathlabs Share Price is Rs 1,947.15. It is below the previous close of Rs 1,987.60, which keeps the latest price action under watch. The stock moved 2.04% lower during the session.
How much did Dr. Lal Pathlabs share price fall today?
Ans. Dr. Lal Pathlabs share price fell by Rs 40.45, or 2.04%, in the latest session. That move extended the second straight session of lower closes and kept the streak in view.
What does the latest valuation say about Dr. Lal Pathlabs Share Price Fall Streak?
Ans. Dr. Lal Pathlabs Share Price Fall Streak leaves the stock at a P/E of 61.56 and a P/B of 12.77. Those are still premium multiples versus the sector median, even after the decline.
How does Dr. Lal Pathlabs compare with healthcare peers?
Ans. Dr. Lal Pathlabs Share Price Fall Streak still sits alongside peers such as Apollo Hospitals, Max Healthcare and Fortis. Its ROE and ROCE remain stronger than some peers, while its valuation remains elevated.
What are the key fundamental numbers for Dr. Lal Pathlabs ?
Ans. Dr. Lal Pathlabs reports EPS of Rs 32.29, book value of Rs 155.67 and dividend yield of 1.03%. ROE is 22.37% and ROCE is 29.56%, which support the fundamental context behind the stock.
What does the sector benchmark show for Dr. Lal Pathlabs Share Price Fall Streak?
Ans. Dr. Lal Pathlabs Share Price Fall Streak is still above the sector median on P/E and P/B. The company’s ROE and ROCE are also above the same-industry median, which keeps the comparison relevant.
Should investors track Dr. Lal Pathlabs Share Price on Univest?
Ans. Investors tracking Dr. Lal Pathlabs Share Price can use Univest to watch price levels, valuation ratios and sector context together. The streak is best read with fundamentals rather than in isolation.
Recent Articles

3B Blackbio Dx Ltd. (3BBLACKBIO): 3B Blackbio Dx Ltd 52 Week High Streak Holds For Second Straight Session
1 October 2026

Lemon Tree Hotels (LEMONTREE) Share Price rises 6.33% as LEMONTREE trades higher
1 October 2026

Maestros Electronics & Telecommunications Systems (METSL) Share Price Rises 8.46% Today
1 October 2026

Infinium Pharmachem Ltd. (INFINIUM) Share Price Rise Streak: Second Straight Session Gains 18.95%
1 October 2026
Note: This blog is for information purpose only. Investments and trading are subject to market risks, read all scheme related documents carefully.
Reviews
Recent Posts
3B Blackbio Dx Ltd. (3BBLACKBIO): 3B Blackbio Dx Ltd 52 Week High Streak Holds For Second Straight Session
Lemon Tree Hotels (LEMONTREE) Share Price rises 6.33% as LEMONTREE trades higher
Maestros Electronics & Telecommunications Systems (METSL) Share Price Rises 8.46% Today
Infinium Pharmachem Ltd. (INFINIUM) Share Price Rise Streak: Second Straight Session Gains 18.95%
Syrma SGS Technology Ltd. (SYRMA) 52 Week High Streak: Consecutive High Analysis
Popular this week
Vikram Solar Ltd. (VIKRAMSOLR): Vikram Solar Share Price Near 52-Week Low as Stock Trades at Rs 157.25

Uniresearch Global Pvt Ltd
Research Analyst
SEBI Registration Number — INH000013776
Uniresearch is a subsidiary of Univest Communication Technologies Private Limited
Company Address: Registered Address: Ground Floor, Unitech Commercial Tower 2, Block B, Greenwood City, Unit 1-3, Sector 45, Gurugram, Haryana 122003
Write to us : support@univest.in, compliance@univest.in
Verify on SEBI registry →RESEARCH ANALYST
Get SEBI Registered
advice on the stocks
trending today.
Get 3 FREE Trade Ideas
for Startups Accelerator 2024
Trusted by 1Cr Indians
Awarded No.1 by Economic Times





